Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Childhood-onset Fluency Disorder Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Childhood-Onset Fluency Disorder
Interventions
NOE-105, Placebo
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Bellflower, California • Jacksonville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced May 22, 2026, 3:46 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Childhood-Onset Fluency Disorder (Stuttering)
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Riverside, California • Santa Ana, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced May 22, 2026, 3:46 AM EDT
Not listed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Stuttering, Adult, Childhood-onset Fluency Disorder, Speech Disorders, Language Disorders, Communication Disorder
Interventions
Ecopipam 50mg, Ecopipam 100mg
Drug
Lead sponsor
Gerald Maguire, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced May 22, 2026, 3:46 AM EDT